摘要
目的 观察ⅢA期胃癌D2根治术后采用同步放化疗的临床效果.方法 将50例D2根治术后的ⅢA期胃癌患者随机分为A组（同步治疗组：甲酰四氢叶酸LV＋5-Fu联合同步放疗,DT 45 Gy/25次.35天）和B组（对照组：LV＋5-Fu化疗）.结果 A组1～3年复发率明显低于B组,8% Vs 20%,8% Vs 32%及16% Vs 60%（P＜0.05）.A组2年及3年生存率明显高于B组64% Vs 48%和48% Vs 32%（P＜0.05）.1年生存率A、B两组无显著性差异,88% Vs 80%（P＞0.05）.结论 同步放、化疗是ⅢA期胃癌D2根治术后较为理想的辅助治疗模式.
Objective To study the results of concurrent chemoradiotherapy for limited-advanced （stage ⅢA） gastric carcinoma. Methods From March 2001 to March 2003,50 Cases Which are stage Ⅲ A gastric cancer operated by D2 gastrectomy randomized into two groups. In group A（25 cases） received concurrent chemoradiotherapy （LV ＋ 5-Fu and DT 45 G y/25f/35d）, and in group B （25 cases） received adjuvant chemotherapy only（LV ＋ 5-Fu）. Results The peritoneal recurrence rate in 1 -3 years were much lower in group A than those of group B,8% Vs 20% ,8% Vs 32% and 16% Vs 60% （P〈0.05）,compared with group B. While 2 and 3 years survival rate were higher, 64 % Vs48 % and 48 % Vs32% （P 〈 0.05 ） ,compared with B group. There was no significant difference in 1 year survival rate between two guoups, 88 % Vs80 %. There is also no significant difference in toxicity and side effect. Conclusion These results demonstrate that concurrent chemordiotherapy is obviously better than adjuvant chemotherapy alone to those patients who are limited-advanced gastric carcinoma.
出处
《实用癌症杂志》
2006年第4期390-391,共2页
The Practical Journal of Cancer
关键词
胃癌
药物疗法
放射疗法
Gastric cancer
Drug therapy
Radiotherapy
